Form 4: Revolution Medicines CEO Exercises Stock Options

Revolution Medicines' President and CEO, Mark A. Goldsmith, exercised options to acquire 24,010 shares of common stock at $0.54 per share.

Summary

• Mark A. Goldsmith, President and Chief Executive Officer of Revolution Medicines, Inc., exercised stock options on February 6, 2026.
• The transaction involved the acquisition of 24,010 shares of common stock at an exercise price of $0.54 per share.
• Following this transaction, Mr. Goldsmith directly beneficially owns 256,479 shares of common stock, which includes 168,763 restricted stock units.
• Mr. Goldsmith also indirectly beneficially owns 570,050 shares through the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust, 67,424 shares through the Jonathan Goldsmith Revocable Trust, and 67,424 shares through the Rebecca Goldsmith Revocable Trust.
• The exercised stock options had a date exercisable of March 1, 2022, and an expiration date of February 11, 2028.
• After the exercise, Mr. Goldsmith directly beneficially owns 144,493 derivative securities (stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event. While it's a routine compensation action, the CEO's decision to exercise options and increase direct ownership can be interpreted as a sign of confidence in the company's future prospects.

Positives

• The CEO's exercise of stock options at a low price of $0.54 per share indicates a commitment to increasing direct ownership in the company.
• The transaction reflects a routine part of executive compensation, aligning management's interests with shareholders.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider option exercises are a common occurrence in the biotechnology industry, often reflecting the execution of long-term compensation plans rather than an immediate market signal. Such transactions are typically pre-scheduled and do not inherently indicate new strategic developments or financial performance shifts.

Related Party Transactions

• Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust holds 570,050 shares of common stock, representing indirect beneficial ownership by the reporting person.
• Jonathan Goldsmith Revocable Trust holds 67,424 shares of common stock, representing indirect beneficial ownership by the reporting person.
• Rebecca Goldsmith Revocable Trust holds 67,424 shares of common stock, representing indirect beneficial ownership by the reporting person.

Stakeholder Impact

• Shareholders may perceive the CEO's increased direct ownership as a positive signal, reinforcing management's alignment with shareholder interests.
• Employees are not directly impacted by this specific insider transaction, as it pertains to executive compensation.

Key Dates

Recommendation

The filing details a routine exercise of stock options by the CEO, which is a common compensation event and does not provide sufficient new information to warrant a change in investment recommendation. It primarily reflects the execution of a pre-existing compensation plan rather than a new market-moving event.

Keywords

Revolution Medicines, RVMD, Mark A. Goldsmith, Stock Option Exercise, Insider Transaction, Form 4, CEO, Biotechnology